Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03107988
Title NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors New Approaches to Neuroblastoma Therapy Consortium
Indications

neuroblastoma

Therapies

Cyclophosphamide + Lorlatinib + Topotecan

Lorlatinib

Age Groups: child | adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST